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Endocan is an important biomarker of inflammation and endothelial dysfunction that increases in association with several chronic
diseases. Few published data have described the role of endocan in pediatric renal transplant (RT) patients. We evaluated the
endocan concentrations in 62 children who underwent renal transplantation and assessed their relationships with the patients’
blood pressure and loss of renal function. The endocan levels were significantly elevated in the pediatric RT patients who had
hypertension and a loss of renal function. We determined positive correlations between the endocan concentrations and the
hemodynamic variables (systolic blood pressure: 𝑟 = 0.416; 𝑃 = 0.001; pulse pressure: 𝑟 = 0.412; 𝑃 = 0.003). The endocan
levels were inversely correlated with the estimated glomerular filtration rate (𝑟 = −0.388; 𝑃 = 0.003). An endocan cutoff
concentration of 7.0 ng/mL identified pediatric RT patients who had hypertension and a loss of renal function with 100% sensitivity
and 75% specificity. In conclusion, the endocan concentrations were significantly elevated in pediatric RT patients who had both
hypertension and a loss of renal function. The correlations between the endocan levels and the hemodynamic variables and the
markers of renal function strengthen the hypothesis that it is an important marker of cardiorenal risk.
1. Introduction
Renal transplantation is one of the most effective options
for the treatment of chronic renal failure in children [1, 2].
Children who receive renal transplants (RTs) have better
survival rates than children who undergo dialysis [3]. In
addition, these children show improvements in the quality of
their lives and their life expectancies [3, 4].
Despite a positive prognosis, concerns continue to exist
about the progressive loss of renal function and the develop-
ment of cardiometabolic diseases among pediatric RT recip-
ients [5–7]. The findings from several studies have demon-
strated that hypertension (HT) is a major cardiovascular
comorbidity that can follow renal transplantation in pediatric
patients [8–11], and the prevalence of HT among these
patients ranges from 60% to 90% [8]. Some investigators have
verified that the development or the persistence of HT during
the posttransplant period is an important risk factor that is
associated with graft loss and survival [8–11]. Indeed, a nega-
tive association betweenHT and the glomerular filtration rate
(GFR) was determined after renal transplantation in children
[9]. While several factors may explain this association, the
underlying mechanism remains unclear. It is possible that
posttransplant HT together with donor and recipient factors,
including the time on dialysis, immunosuppressive therapy,
the timing of the transplantation, and the donor’s age,
converge to negatively impact upon the GFR.
The findings from recent research indicate that endocan
could be an important predictive marker of arterial HT and
renal failure [12–14]. Endocan is a soluble dermatan sulfate
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proteoglycan that is expressed by the human endothelial
cells that are present in many different vascular beds [15,
16]. Its expression is regulated by inflammatory cytokines
that induce the upregulation of endocan messenger ribonu-
cleic acid, and the molecule is subsequently released by
the endothelial cells [17]. Several reports indicate that the
endocan concentrations negatively impact upon the severity
of illnesses and the clinical outcomes [14, 18, 19].The purpose
of this study was to analyze the endocan concentrations in
pediatric patients during the 6–24-month period after renal
transplantation. We also assessed the relationships between
the endocan levels and the patients’ blood pressure and loss
of renal function.
2. Methods
This study was conducted at the Renal Transplant Unit of the
Nephrology Division from Kidney & Hypertension Hospital
(Federal University of Sa˜o Paulo; UNIFESP-EPM, Sa˜o Paulo,
Brazil) on pediatrics patients, who were recruited between
August 2013 and July 2014. The study was carried out on 62
RT children (43 boys and 19 girls). Inclusion criteria were as
follows: RT patients of either sex; patients who were between
6 and 24months after transplant. On the other hand, patients
were excluded for the following reasons: presence of systemic
infection or acute rejection clinically diagnosed and biopsy
proven. None of the childrenwho underwent renal transplant
received vitamin D supplementation. All patients provided a
blood sample, which was collected in the morning, following
an overnight fast. After that, the body weight and height
were measured using a standard balance beam scale. The
local ethics committee approved the study protocol (Protocol
Number: 354.875). All parents and children signed written
informed consent/assent forms.
2.1. Measurement of Blood Pressure Levels. Systolic (SBP)
and diastolic (DBP) blood pressure were measured with
appropriate cuff size by auscultation after the child was seated
for 10min. We defined HT in accordance with the Fourth
National Task Force on High Blood Pressure in Children
and Adolescents [20]. AnHT diagnosis was established when
three or more assessments of the SBP and/or the DBP on
different days over a 21-day interval were above the 95th per-
centiles at 6 months after transplant. We calculated the pulse
pressure (PP) using the following formula: PP = SBP − DBP.
2.2. Renal Function Assay. The serum creatinine (sCr) levels
were measured using an automated picric acid assay and a
Hitachi 717 analyzer in accordance with the manufacturers’
instructions. The estimated GFR (eGFR) was determined
based on the sCr levels using the Bedside Schwartz equation,
as follows: (eGFR = 0.413 × height (cm)/Scr [mg/dL] =
mL/min/1.73m2) [21].
2.3. Endocan Measurement. The serum endocan levels were
measured using a magnetic bead-based immunoassay kit
(HCVD1MAG-67K–1 Plex; Merck Millipore, Billerica, MA,
USA), according to the manufacturer’s protocol. The assay’s
concentration range was 0.02–9.6 ng/mL.The intra-assay and
interassay coefficients of variation for the endocan assay were
<2.43% and <5.57%, respectively. Neither significant cross-
reactivity nor interference between human endocan and the
breakdown product, which is a p14 peptide fragment, has
been reported.
2.4. Statistical Analysis. The categorical variables are pre-
sented as the frequencies and the percentage distribu-
tions. The continuous variables were assessed for normality
before the data were analyzed, and they are summarized
as the means, standard deviations, and the 95% confidence
intervals (CIs). The analyses were performed by stratify-
ing the pediatric RT patients according to the chronic
kidney disease (CKD) cutoff point, namely, an eGFR of
<60mL/min/1.73m2, and the presence or absence of HT
[20, 22]. To examine the effects of HT and CKD on the
endocan levels, we performed a two-way analysis of variance
(ANOVA) followed by pairwise multiple comparisons using
the Bonferroni test that examined the significance of themain
effect and/or the interactions between HT and CKD. Cor-
relations between the continuous variables were determined
using Pearson’s correlation coefficient. Furthermore, logistic
regression analyses were performed. Variables that showed a
tendency towards a correlation and had a value of 𝑃 < 0.20
in the univariate model were included in the multivariate
analysis. A receiver operating characteristic (ROC) curve was
applied to identify the best endocan cutoff point. All of the
statistical tests were two-tailed, and the significance level was
set at 𝑃 < 0.05. The statistical analyses were performed
using IBMSPSS software (Version 22, IBM Corporation,
Armonk, NY, USA).
3. Results
Our study cohort comprised 62 pediatric RT patients, and
67% of the patients were boys.Themean age of the recipients
at transplantation was 12.8 years (range: 3–17 years), and the
mean age of the donors was 12.7 years (range: 2–43 years).
Six of the donors were adults and 56 donors were younger
than 18 years of age. The causes of renal failure were defined
as uropathy in 22.6% and glomerulonephritis in 17.7% of
the patients, and the etiologies were undetermined or the
renal failure was associated with other causes in 59.7% of the
RT patients (Table 1). After renal transplantation, 29 of 62
(46.8%) children had CKD, which was defined as an eGFR
< 60mL/min/1.73m2. HT was detected in 44 of the children
before renal transplantation, and HT persisted in 29 of the
children after transplantation. Sixteen children had both HT
and CKD after renal transplantation, and 20 children had
neither HT nor CKD. Seventeen children (26%) were given
steroid-free immunosuppressive therapy and seven children
(25%) were given single agent antihypertensive therapy that
comprised calcium channel blockers (CCBs). Demographic,
anthropometric, and clinical data are presented in Tables 1
and 2.
The mean endocan concentration was 12.2 ng/mL (range:
4.3–15.4 ng/mL), and there was no significant difference
between the genders with respect to the endocan concen-
tration (𝑃 = 0.252). There were no correlations between
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Table 1: Clinical characteristics of the study population at renal
transplant.
Characteristic
Age at transplantation (years) 12.8 (3.51)
(11.9–13.8)
Male gender 43 (69)




Recurrent urinary tract infections 2 (3)
Hemolytic-uremic syndrome 2 (3)
Multicystic dysplastic kidney 2 (3)
Nephropathic cystinosis 1 (1.6)




CAPD + HD 6 (10)
No dialysis 5 (8)
Time on chronic dialysis (months) 15.8 (9.66)(12.9–18.7)
Preexisting hypertension 44 (55)
Deceased donor 60 (96.8)
Male donor 40 (66)
Donor age 12.7 (8.7)(10.3–15.1)
Acute rejection 9 (15)
Delayed graft function 22 (36)
Cold ischemia time (min) 1265.6 (360.8)(1158.4–1372.7)
Renal artery stenosis 2 (3.2)
Data are reported as number with percent in parentheses or mean with
standard deviation and 95% confidence interval in parentheses. CAKUT:
congenital anomalies of the kidney and the urinary tract; HD: hemodialysis;
CAPD: continuous ambulatory peritoneal dialysis.
the endocan levels and age (𝑟 = 0.120; 𝑃 > 0.05) or the
body mass index (BMI) (𝑟 = 0.107; 𝑃 > 0.05). We found
positive correlations between the endocan levels and the SBP
(𝑟 = 0.416; 𝑃 = 0.001) and the PP (𝑟 = 0.412; 𝑃 =
0.003) (Figures 1(a) and 1(b)). These correlations remained
significant after adjusting for gender, age, BMI, and the time
on chronic dialysis (SBP: 𝑟 = 0.333; 𝑃 = 0.018 and PP:
𝑟 = 0.358 and 𝑃 = 0.011). The serum endocan levels
did not change significantly when immunosuppressive or
antihypertensive agents were administered (both 𝑃 > 0.05).
Inverse correlations were detected between the eGFR and the
SBP (𝑟 = −0.274; 𝑃 = 0.037) and the PP (𝑟 = −0.281; 𝑃 =
0.032). Interestingly, endocan levels were inversely correlated
with the eGFR (𝑟 = −0.388; 𝑃 = 0.003).
The two-way ANOVA revealed the significant effects of
HT (𝐹 = 5.989; 𝑃 = 0.017) and CKD (𝐹 = 25.959; 𝑃 < 0.001)
on the serum endocan concentrations (Figure 2(a)). Pediatric
Table 2: Characteristics of the study population after transplanta-
tion.
Characteristic
Age (years) 14.5 (3.3)(13.6–15.4)
Height (cm) 149.5 (16.6)(144.9–154.1)
Weight (Kg) 45.5 (16.2)(41.0–49.6)
BMI (Kg/m2) 19.9 (4.5)(18.6–21.2)
SBP (mmHg) 125 (13.5)(121–128)
DBP (mmHg) 83 (12.4)(80–87)
PP (mmHg) 42 (13.2)(38–45)
sCr (mg/dL) 1.01 (0.28)(0.93–1.09)
eGFR (mL/min/1.73m2) 64.3 (17.6)(59.4–69.2)
Endocan (ng/mL) 12.5 (4.2)(11.3–13.6)
Immunosuppressive therapy
TAC + MMF + AZA 5 (8)
AZA + MMF 12 (18)
PRED + AZA + CSA 4 (6)
PRED + TAC + AZA 32 (53)
PRED + TAC 9 (15)
Antihypertensive therapy
ACE-I + CCBs 4 (14)
ACE-I + ARBs 5 (18)
ARBs + CCBs + 𝛽-blockers 4 (14)
Diuretics + CCBs + 𝛽-blockers 8 (29)
CCBs 7 (25)
Data are reported as number with percent in parentheses or mean with
standard deviation and 95% confidence interval in parentheses. BMI: body
mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
PP: pulse pressure; sCr: serum creatinine; eGFR: glomerular filtration rate
estimated by creatinine; TAC: tacrolimus; MMF: mycophenolate mofetil;
AZA: azathioprine; CSA: cyclosporine A; PRED: prednisone; ACE-I: ACE
inhibitors; CCBs: calcium channel blockers; ARBs: angiotensin receptor
blockers.
RT patients with HT and CKD (𝑛 = 16) had a significantly
higher mean serum endocan concentration (15.4 ng/mL; 95%
CI: 13.8–17.2) compared with that in the pediatric RT patients
who did not have either of these conditions (𝑛 = 20)
(8.9 ng/mL; 95% CI: 7.4–10.5) (𝑃 < 0.001) and the mean
serum endocan concentration in those with HT only (𝑛 =
13) (10.8 ng/mL; 95% CI: 8.9–12.6) (𝑃 = 0.002). There was
no significant difference with respect to the mean serum
endocan concentration between the pediatric RT patients
with HT and CKD and those with CKD only (𝑛 = 13)
(13.1 ng/mL; 95% CI: 11.2–14.9) (𝑃 = 0.342) (Figure 2(b)).
The mean serum endocan concentration in the pediatric RT
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Figure 1: Scatter plots showing the correlations between endocan with (a) systolic blood pressure (𝑟 = 0.416; 𝑃 = 0.001) and endocan with
































































Figure 2: (a) Interaction plot of the mean endocan levels in RT children (𝑛 = 62) according to presence or not of the hypertension (HT)
and/or chronic kidney disease (CKD). Statistical analysis: two-way analysis of variance (ANOVA) method. (b) Changes in the endocan levels
in RT children with both HT and CKD (HTCKD; 𝑛 = 16), with HT without CKD (HT w/o CKD; 𝑛 = 13), with CKD without HT (CKD
w/o HT, 𝑛 = 13), and without both conditions (w/o HTCKD; 𝑛 = 20). The bars indicate standard error of mean. Statistical analysis: two-
way analysis of variance (ANOVA) followed by pairwise multiple comparison (Bonferroni test) method. ∗𝑃 < 0.001 versus w/o HTCKD;
#𝑃 = 0.002 versus HT w/o CKD; ¥𝑃 = 0.007 versus w/o HTCKD.
patients with only CKD was significantly higher compared
with that in the pediatric RT patients who did not have HT
or CKD (𝑃 = 0.007) (Figure 2(b)).
We performed logistic regression analyses to identify
the risk factors associated with HT and the loss of renal
function in the pediatric RT patients. The univariate analysis
showed that donor age, a male donor, the PP, and the use
of prednisone tended to be associated with these dependent
variables (𝑃 < 0.20) (Table 3). The endocan levels were
independently associated with the presence of HT and the
loss of renal function in the pediatric RT patients (Table 3).
The multivariate logistic regression analysis determined that
only the endocan levels were independently associated with
the presence of HT and the loss of renal function in our study
population (Table 3). The ROC curve analysis demonstrated
that an endocan cutoff concentration of 7.0 ng/mL could
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OR (95% CI) 𝑃 value OR (95% CI) 𝑃 value
Age (per years) 1.110 (0.884–1.395) 0.369
Male gender (no/yes) 1.333 (0.269–5.606) 0.725
BMI (per Kg/m2) 1.066 (0.902–1.260) 0.456
Pulse pressure (mmHg) 1.084 (1.015–1.157) 0.016 1.079 (0.969–1.202) 0.166
Endocan (per ng/mL) 1.855 (1.187–2.898) 0.007 2.070 (1.097–3.907) 0.035
Donor age (per year) 0.832 (0.708–0.978) 0.086 0.839 (0.659–1.085) 0.317
Male donor (no/yes) 1.367 (0.860–1.767) 0.176 1.317 (0.448–4.577) 0.399
Preexisting hypertension
(no/yes) 4.437 (0.449–9.723) 0.224
Chronic dialysis (per months) 1.021 (0.932–1.120) 0.652
Delayed graft function (no/yes) 1.592 (0.382–6.625) 0.523
Cold ischemia time (per min) 1.048 (0.258–4.256) 0.948
Prednisone (no/yes) 1.640 (0.168–2.436) 0.198 1.486 (0.743–5.987) 0.567
Tacrolimus (no/yes) 2.213 (0.467–7.238) 0.298
Mycophenolate mofetil (no/yes) 1.201 (0.221–5.521) 0.833
Azathioprine (no/yes) 0.400 (0.109–1.254) 0.251
Data are reported as odds ratio (OR) and 95% confidence interval (95% CI).
identify pediatric RT patients with both HT and the loss of
renal function with a sensitivity of 100% and a specificity of
75% (area under the curve: 0.894; standard error: 0.053; 95%
CI: 0.790–0.998; 𝑃 < 0.001) (Figure 3).
4. Discussion
The main finding of present study is that serum endocan
levels were significantly elevated in RT children with both
HT and loss of renal function and that the serum endocan
concentration was an independent predictor of the presence
of HT and a loss of renal function in pediatric RT patients,
after adjusting for multiple confounders. In addition, we
found positive correlation of endocan with SBP and pulse
pressure, and the serum levels of this biomarker were
inversely correlated with eGFR among RT children.
Endocan is a soluble proteoglycan that is detected in the
blood and is expressed by endothelial cells of the vasculature,
lung, and kidney [16, 17]. There is strong evidence to support
its role in several chronic diseases and that suggests that it is
an important biomarker of endothelial function [13, 18, 19].
The findings from a recent study showed that patients with
type 2 diabetes who had microalbuminuria had lower endo-
can levels [23], and the investigators suggested that higher
levels of endocanmay be present in the early phase of diabetic
nephropathy and that the levels of endocan decline as the
disease progresses [23]. To date, few studies have evaluated
the role of the endocan levels in RT patients. The findings
from a study by Li et al. [24] showed that the circulating
endocan level could be used as a marker of acute rejection in
RT patients. In another report, high levels of endocan were
ROC curve
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Figure 3: Receiver operating characteristic (ROC) curve of endocan
levels predicting presence of both hypertension and loss renal
function in RT children.
correlated with different stages of the CKD in RT patients
[25]. These authors also observed that GFR loss was greater
in the group with higher serum endocan levels [25]. In
addition, negative correlations have been described between
the endocan levels and the eGFR and endothelial function
6 International Journal of Nephrology
in patients with CKD who had not undergone hemodialysis
or peritoneal dialysis [13]. Our results concur with and
extend the findings from these studies, and they link high
endocan levels with HT and GFR reductions in RT patients.
Another interesting finding was the positive association
between the endocan levels and the PP. Furthermore, we
found that pediatric RT patients who had HT and a loss
of renal function also had higher PPs compared with the
pediatric RT patients who did not have these conditions.
The PP elevations observed in these children might indicate
the presence of arterial stiffness that leads to adverse cardio-
vascular outcomes. The impairment of the elastic properties
of the vasculature is widely regarded as a factor that could
contribute to the development and/or the persistence of HT
and CKD progression [26]. Interestingly, endocan is involved
in the development of vascular tissue under physiological and
pathological conditions [27–30]. An important consideration
is that treatment with antihypertensive and/or immunosup-
pressive agents may have an effect on the endocan levels.
Some drugs, including angiotensin II receptor blockers,
tacrolimus, and CCBs, promote alterations in endothelial
function that could also influence the circulating endocan
levels [31, 32]. In the current study, there were no significant
changes in the serumendocan levels thatwere associatedwith
the administration of immunosuppressive or antihyperten-
sive therapy. Therefore, therapeutic scheme in the RT patient
should be taken into account which makes the interpretation
of endocan data among these patients even more difficult.
Some mechanisms could explain the high endocan levels
in the pediatric RT patients with HT and the loss of renal
function. The findings from recent studies have shown links
between the endocan levels and endothelial dysfunction
and inflammation [13, 18, 19]. Endocan is expressed by the
endothelium, and in response to endothelial damage or
the presence of inflammatory cytokines, including tumor
necrosis factor-alpha and interleukin-1 beta, the endothelial
cells upregulate the expression and secretion of endocan [15–
17]. Endocan may stimulate the proliferation and migration
of vascular smooth muscle cells [33]. Since endothelial
dysfunction and inflammatory factors are associated with the
development of HT and other cardiovascular diseases in RT
patients, it is possible that the presence of these conditions
could, at least in part, reflect the processes that were involved
in increasing the endocan levels in our study population.
Moreover, the increase in the endocan levels in patients with
CKD may be a consequence of a reduction in its renal clear-
ance [13]. We did not collect urine samples from the patients
in the present study; therefore, we could not compare the
fractional excretions of endocan in the pediatric RT patients.
However, based on data recently reported in the literature, the
high endocan levels in the pediatric RTpatients do not appear
to have been caused by reductions in the renal clearance of
endocan, which results in high concentrations of endocan
in the plasma [31]. Endocan is a negatively charged 50 kDa
proteoglycan; therefore, under physiological conditions it
cannot pass through the glomerular filtration barrier [17, 31].
Indeed, recent study found that endocan was undetectable or
was present at very low levels in urine samples from healthy
individuals [31]. The same investigators also found that both
the plasma and the urinary concentrations of endocan were
high in patients with immunoglobulin A nephropathy, which
suggests that the presence of glomerular injury that involves
the disruption of the basement membrane in patients with
pathological renal conditions could promote endocan excre-
tion into the urine [31]. Thus, more knowledge about renal
handling of endocan is required to help us understand the
mechanisms involved in the production of endocan and its
clearance from the circulation via the kidney in RT patients.
The limitations of the present study include the small
number of patients recruited, its cross-sectional design, and
the single rather than multiple measurements of the serum
endocan concentrations. In conclusion, pediatric RT patients
with both HT and a loss of renal function have elevated
endocan levels. The presence of correlations between the
endocan levels and the SBP, the PP, and the eGFR strengthens
the hypothesis that endocan is an important marker of
cardiorenal risk. Although the pathological implications are
not completely understood, the data from this study may
help to explain the kidney damage and the increased risks of
HT and other cardiovascular diseases that occur in pediatric
RT patients. Further studies are necessary to clarify the
importance of these correlations and to elucidate the clinical
significance of endocan.
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